TABLE 1.
Literature review
| Authors & Year | Age (yrs)/Sex | Tumor Type | Op Approach | Op to HOD Diagnosis, mos | HOD Site | HOD Symptoms |
|---|---|---|---|---|---|---|
| Akar et al., 200812 | 27/F | PA | — | 2 | Lt | — |
| Hirano et al., 201513 | 40/M | Medulloblastoma | — | 0 | Bilat | — |
| 46/M | Low-grade glioneuronal | — | 3 | Bilat | — | |
| 42/M | Medulloblastoma | — | 4 | Bilat | — | |
| 55/F | PA | — | 7 | Bilat | — | |
| Khayat et al., 201914 | 45/F | Anaplastic ependymoma | — | 9 | Bilat | PT |
| Lana et al., 201815 | 70/M | Oligodendroglioma | Midline telovelar | 3 | Bilat | PT |
| McDonald et al., 202216 | 25/M | PA | — | 3 | Lt | PT |
| Schaller-Paule et al., 202111 | 20/F | PA | Paravermal | 2 | Rt | — |
| 60/F | PA | Paravermal | 8 | Rt | — | |
| 32/M | PA | Paravermal | 6 | Lt | — | |
| 35/M | Ependymoma | Midline telovelar | 3 | Lt | — | |
| 34/M | Medulloblastoma | Midline telovelar | 10 | Bilat | — | |
| 40/M | Medulloblastoma | Paravermal + telovelar | 3 | Rt | — | |
| Schaller-Paule et al., 201917 | 26/M | Medulloblastoma | — | 9 | Bilat | — |
| 19/F | Medulloblastoma | Midline telovelar | 8 | Bilat | PT | |
| 35/M | Medulloblastoma | Midline telovelar | 10 | Bilat | — | |
| 41/M | Medulloblastoma | Midline telovelar | 3 | Rt | PT | |
| Shinohara et al., 201310 | 57/F | Breast metastasis | — | 1 | Lt | — |
| 79/M | Lung metastasis | — | 3 | Rt | — | |
| 41/F | Ependymoma | — | 1 | Bilat | — | |
| 58/M | Brainstem glioma | — | 1 | Bilat | — | |
| Vaidhyanath et al., 201018 | 57/M | Epidermoid cyst | — | 6 | Bilat | PT |
PA = pilocytic astrocytoma; PT = palatal tremor; — = not available.
The characteristics of 23 adult patients with hypertrophic olivary degeneration (HOD) development after resection of midline posterior cranial fossa (PCF) tumors are shown. Surgery to diagnosis of HOD is defined as the length of time between tumor resection and discovery of inferior olivary nucleus (ION) hyperintensity on T2/FLAIR MR Iimaging.10–18